Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections

Enhanced and sustained decrease in the incidence and severity of infection at a community hospital

P. J. Maziade, J. A. Andriessen, P. Pereira, B. Currie, E. J C Goldstein

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: In 2003, hospitals in Quebec, Canada experienced an increase of NAP1/027 Clostridium difficile infections following antibiotic administration (CDIAA). At Pierre-Le Gardeur Hospital (PLGH), the incidence increased from 10 to over 25 cases per 1000 patient admissions. Methods: We report a quasi-experimental, prospective cohort study evaluating the effect on CDIAA of a probiotic added to existing C. difficile infection (CDI) standard preventative measures (SPM) in 31,832 hospitalized patients receiving antibiotics. Phase I (1580) measured the impact of SPM alone. In Phase II, 50 to 60 × 10 9 cfu daily dose of oral Lactobacillus acidophilus CL1285 and L. casei LBC80R probiotic formula (Bio-K+)* was administered to all patients receiving antibiotics. Phase III included the same intervention after a move to a new hospital facility. Phases II and III included 4968 patients. During Phase IV, 25,284 patients were submitted to the same regimen but outcome data were compared to those of similar hospitals in Quebec. Results: At the end of Phase III, CDIAA had decreased from more than 18 cases per 1000 patient admissions in Phase I to less than 5 cases. Reductions of CDI cases (73%) (p < 0.001) and severe CDI cases (76.4%) (p < 0.001) were observed. CDI recurrence rate was reduced by 39% (p < 0.001). During the following 6 years, the CDI rate averaged 2.71 cases per 10,000 patient-days at PLGH compared to 8.50 cases per 10,000 patient-days in equivalent hospitals located in Quebec. Study limitation: This study is not a randomized clinical trial; it is an open prospective study and should be treated as such. Also, following Phase II, PLGH moved into a new facility and this could have contributed to lower CDI. Conclusions: Specific probiotic product added to SPM and antibiotic stewardship activities resulted in a further reduction in CDI rates and was shown to be safe.

Original languageEnglish (US)
Pages (from-to)1341-1347
Number of pages7
JournalCurrent Medical Research and Opinion
Volume29
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Clostridium Infections
Clostridium difficile
Community Hospital
Probiotics
Incidence
Infection
Anti-Bacterial Agents
Quebec
Patient Admission
Prospective Studies
Lactobacillus acidophilus
Canada
Cohort Studies
Randomized Controlled Trials

Keywords

  • Antibiotic
  • Clostridium difficile infection
  • Lactobacillus acidophilus CL1285
  • Lactobacillus casei LBC80R
  • Probiotic
  • Quasi-experimental design

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections : Enhanced and sustained decrease in the incidence and severity of infection at a community hospital. / Maziade, P. J.; Andriessen, J. A.; Pereira, P.; Currie, B.; Goldstein, E. J C.

In: Current Medical Research and Opinion, Vol. 29, No. 10, 10.2013, p. 1341-1347.

Research output: Contribution to journalArticle

@article{e47fad3ea12a4f2dac87b933331b51d7,
title = "Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: Enhanced and sustained decrease in the incidence and severity of infection at a community hospital",
abstract = "Background: In 2003, hospitals in Quebec, Canada experienced an increase of NAP1/027 Clostridium difficile infections following antibiotic administration (CDIAA). At Pierre-Le Gardeur Hospital (PLGH), the incidence increased from 10 to over 25 cases per 1000 patient admissions. Methods: We report a quasi-experimental, prospective cohort study evaluating the effect on CDIAA of a probiotic added to existing C. difficile infection (CDI) standard preventative measures (SPM) in 31,832 hospitalized patients receiving antibiotics. Phase I (1580) measured the impact of SPM alone. In Phase II, 50 to 60 × 10 9 cfu daily dose of oral Lactobacillus acidophilus CL1285 and L. casei LBC80R probiotic formula (Bio-K+)* was administered to all patients receiving antibiotics. Phase III included the same intervention after a move to a new hospital facility. Phases II and III included 4968 patients. During Phase IV, 25,284 patients were submitted to the same regimen but outcome data were compared to those of similar hospitals in Quebec. Results: At the end of Phase III, CDIAA had decreased from more than 18 cases per 1000 patient admissions in Phase I to less than 5 cases. Reductions of CDI cases (73{\%}) (p < 0.001) and severe CDI cases (76.4{\%}) (p < 0.001) were observed. CDI recurrence rate was reduced by 39{\%} (p < 0.001). During the following 6 years, the CDI rate averaged 2.71 cases per 10,000 patient-days at PLGH compared to 8.50 cases per 10,000 patient-days in equivalent hospitals located in Quebec. Study limitation: This study is not a randomized clinical trial; it is an open prospective study and should be treated as such. Also, following Phase II, PLGH moved into a new facility and this could have contributed to lower CDI. Conclusions: Specific probiotic product added to SPM and antibiotic stewardship activities resulted in a further reduction in CDI rates and was shown to be safe.",
keywords = "Antibiotic, Clostridium difficile infection, Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, Probiotic, Quasi-experimental design",
author = "Maziade, {P. J.} and Andriessen, {J. A.} and P. Pereira and B. Currie and Goldstein, {E. J C}",
year = "2013",
month = "10",
doi = "10.1185/03007995.2013.833501",
language = "English (US)",
volume = "29",
pages = "1341--1347",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections

T2 - Enhanced and sustained decrease in the incidence and severity of infection at a community hospital

AU - Maziade, P. J.

AU - Andriessen, J. A.

AU - Pereira, P.

AU - Currie, B.

AU - Goldstein, E. J C

PY - 2013/10

Y1 - 2013/10

N2 - Background: In 2003, hospitals in Quebec, Canada experienced an increase of NAP1/027 Clostridium difficile infections following antibiotic administration (CDIAA). At Pierre-Le Gardeur Hospital (PLGH), the incidence increased from 10 to over 25 cases per 1000 patient admissions. Methods: We report a quasi-experimental, prospective cohort study evaluating the effect on CDIAA of a probiotic added to existing C. difficile infection (CDI) standard preventative measures (SPM) in 31,832 hospitalized patients receiving antibiotics. Phase I (1580) measured the impact of SPM alone. In Phase II, 50 to 60 × 10 9 cfu daily dose of oral Lactobacillus acidophilus CL1285 and L. casei LBC80R probiotic formula (Bio-K+)* was administered to all patients receiving antibiotics. Phase III included the same intervention after a move to a new hospital facility. Phases II and III included 4968 patients. During Phase IV, 25,284 patients were submitted to the same regimen but outcome data were compared to those of similar hospitals in Quebec. Results: At the end of Phase III, CDIAA had decreased from more than 18 cases per 1000 patient admissions in Phase I to less than 5 cases. Reductions of CDI cases (73%) (p < 0.001) and severe CDI cases (76.4%) (p < 0.001) were observed. CDI recurrence rate was reduced by 39% (p < 0.001). During the following 6 years, the CDI rate averaged 2.71 cases per 10,000 patient-days at PLGH compared to 8.50 cases per 10,000 patient-days in equivalent hospitals located in Quebec. Study limitation: This study is not a randomized clinical trial; it is an open prospective study and should be treated as such. Also, following Phase II, PLGH moved into a new facility and this could have contributed to lower CDI. Conclusions: Specific probiotic product added to SPM and antibiotic stewardship activities resulted in a further reduction in CDI rates and was shown to be safe.

AB - Background: In 2003, hospitals in Quebec, Canada experienced an increase of NAP1/027 Clostridium difficile infections following antibiotic administration (CDIAA). At Pierre-Le Gardeur Hospital (PLGH), the incidence increased from 10 to over 25 cases per 1000 patient admissions. Methods: We report a quasi-experimental, prospective cohort study evaluating the effect on CDIAA of a probiotic added to existing C. difficile infection (CDI) standard preventative measures (SPM) in 31,832 hospitalized patients receiving antibiotics. Phase I (1580) measured the impact of SPM alone. In Phase II, 50 to 60 × 10 9 cfu daily dose of oral Lactobacillus acidophilus CL1285 and L. casei LBC80R probiotic formula (Bio-K+)* was administered to all patients receiving antibiotics. Phase III included the same intervention after a move to a new hospital facility. Phases II and III included 4968 patients. During Phase IV, 25,284 patients were submitted to the same regimen but outcome data were compared to those of similar hospitals in Quebec. Results: At the end of Phase III, CDIAA had decreased from more than 18 cases per 1000 patient admissions in Phase I to less than 5 cases. Reductions of CDI cases (73%) (p < 0.001) and severe CDI cases (76.4%) (p < 0.001) were observed. CDI recurrence rate was reduced by 39% (p < 0.001). During the following 6 years, the CDI rate averaged 2.71 cases per 10,000 patient-days at PLGH compared to 8.50 cases per 10,000 patient-days in equivalent hospitals located in Quebec. Study limitation: This study is not a randomized clinical trial; it is an open prospective study and should be treated as such. Also, following Phase II, PLGH moved into a new facility and this could have contributed to lower CDI. Conclusions: Specific probiotic product added to SPM and antibiotic stewardship activities resulted in a further reduction in CDI rates and was shown to be safe.

KW - Antibiotic

KW - Clostridium difficile infection

KW - Lactobacillus acidophilus CL1285

KW - Lactobacillus casei LBC80R

KW - Probiotic

KW - Quasi-experimental design

UR - http://www.scopus.com/inward/record.url?scp=84884486438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884486438&partnerID=8YFLogxK

U2 - 10.1185/03007995.2013.833501

DO - 10.1185/03007995.2013.833501

M3 - Article

VL - 29

SP - 1341

EP - 1347

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

ER -